Acute minor ischemic stroke presents a crucial clinical window where rapid intervention prevents early recurrent cerebrovascular events. Standard clinical management frequently utilizes antiplatelet agents to mitigate secondary ischemic risks. However, determining the optimal dual antiplatelet therapy duration remains a critical challenge for clinicians treating patients presenting up to 72 hours after symptom onset. While early clinical trials established clear efficacy for immediate antiplatelet combination, real-world presentation often occurs outside the hyperacute 24-hour therapeutic window. A prospective cohort study recently evaluated whether short-term combined antiplatelet regimens offer sustained vascular protection without compromising patient safety through major hemorrhagic complications.

Background and Clinical Rationale for Antiplatelet Regimens

Managing acute minor ischemic stroke requires balancing early recurrent thrombosis prevention against cumulative major hemorrhagic risks. Pioneer trials, including CHANCE and POINT, demonstrated that combining aspirin with clopidogrel significantly reduces secondary stroke recurrence when initiated within 24 hours of symptom onset. Consequently, guidelines widely recommend dual antiplatelet regimens for high-risk transient ischemic attack and minor non-cardioembolic stroke. However, many patients present to medical centers beyond the first 24 hours. Consequently, clinicians frequently face uncertainty regarding whether initiating or continuing dual therapy provides substantial benefit within an extended window of up to 72 hours. Furthermore, prolonged combined antiplatelet therapy carries a recognized spillover effect, where gastrointestinal and intracranial bleeding risks gradually outweigh ischemic prevention. Therefore, identifying the precise therapeutic window and treatment length is essential. Researchers conducted this prospective observational study to address this knowledge gap directly. The investigators specifically evaluated how varying treatment durations influence composite vascular outcomes and severe bleeding risks among patients presenting with non-cardioembolic minor ischemic stroke within 72 hours of symptom onset.

Study Design and Methodology of the Prospective Cohort

The investigators analyzed data from the Safety and Efficacy of Aspirin-Clopidogrel in Acute Noncardiogenic Minor Ischemic Stroke study. This prospective multicenter cohort study enrolled patients presenting with acute minor ischemic stroke, defined as a National Institutes of Health Stroke Scale (NIHSS) score of 5 or lower, within 72 hours of symptom onset. Overall, the study included 3,061 eligible participants with a mean age of 61.7 years, of whom 73.3% were male. The median baseline NIHSS score was 2, reflecting a typical cohort of mild, non-disabling cerebrovascular events. A total of 97.4% of participants completed the full 90-day observational follow-up period. Treatment assignment reflected real-world clinical practice, dividing participants into single antiplatelet therapy (39.0%) and dual antiplatelet therapy (61.0%) groups. To evaluate treatment length, researchers categorized the dual therapy cohort into three distinct subgroups based on administration duration: shorter duration (less than 10 days, 16.8%), short duration (10 to 21 days, 51.7%), and long duration (greater than 21 days, 31.5%). Propensity-weighted Cox proportional hazards regression models and propensity score-matching analyses adjusted for baseline clinical imbalances.

Key Efficacy Outcomes and Vascular Event Reduction

The primary efficacy outcome was a composite of recurrent vascular events over a 90-day follow-up period, including recurrent ischemic stroke, myocardial infarction, and vascular death. In propensity-weighted analysis, patients receiving a short dual antiplatelet therapy duration of 10 to 21 days demonstrated a statistically significant reduction in composite vascular events compared to those managed with single antiplatelet monotherapy. Specifically, the short-duration group achieved a hazard ratio of 0.66 (95% confidence interval 0.46 to 0.94, p = 0.02), representing a 34% relative risk reduction in major 90-day vascular events. Propensity score-matched analyses confirmed these robust findings, reinforcing the clinical superiority of a 10 to 21-day combined regimen. In contrast, shorter treatment durations of less than 10 days failed to demonstrate consistent protection, likely because brief platelet inhibition is insufficient to cover the highest risk period for early stroke recurrence. Similarly, extending dual antiplatelet administration beyond 21 days provided no significant incremental protection against recurrent ischemic events. Thus, these findings highlight a specific therapeutic sweet spot between 10 and 21 days where antithrombotic efficacy is maximized.

Evaluating Safety Profiles and Hemorrhagic Risk

Safety considerations represent a paramount priority when prescribing intensive antithrombotic regimens for cerebrovascular disease. The primary safety outcome evaluated severe bleeding events during the 90-day post-stroke period. Reassuringly, the incidence of severe hemorrhagic complications in the short-duration dual therapy group (10 to 21 days) was comparable to single antiplatelet therapy alone. Propensity-weighted analyses demonstrated no significant increase in severe bleeding events, indicating that a brief 10 to 21-day course of combined aspirin and clopidogrel maintains a favorable safety profile. However, clinicians must remain vigilant regarding extended dual antiplatelet administration. Historically, trials evaluating prolonged dual therapy beyond three weeks documented progressive increases in major gastrointestinal and systemic bleeding without proportional reduction in ischemic recurrence. By restricting the combined regimen to 21 days maximum, practitioners successfully avoid the cumulative hemorrhagic spillover effect. Therefore, this prospective cohort confirms that a tailored 10 to 21-day dual antiplatelet strategy effectively balances potent antiischemic protection against severe bleeding risks in patients presenting within 72 hours.

Clinical Implications for Real-World Secondary Stroke Prevention

These findings carry major clinical implications for emergency clinicians, internists, and neurologists managing acute cerebrovascular events in daily practice. In real-world care, patients frequently present beyond the traditional 24-hour window due to delayed symptom recognition or transfer delays. Demonstrating that short-duration dual antiplatelet therapy retains efficacy when initiated within 72 hours expands the therapeutic window for secondary stroke prevention. Furthermore, the study offers clear guidance on the optimal timeframe for dual antiplatelet administration. Rather than maintaining combined therapy indefinitely or discontinuing it prematurely, clinicians should target a 10 to 21-day treatment course before transitioning patients to long-term monotherapy. This approach aligns well with current pathophysiological understanding, as local plaque stabilization and thrombosis risk diminish significantly after the initial three weeks. Consequently, adopting a structured 10 to 21-day protocol can improve standardized post-stroke care, optimize resource utilization, and reduce recurrent vascular hospitalizations. Medical practitioners should review local stroke protocols to incorporate these duration-specific recommendations for eligible patients presenting with minor ischemic stroke.

Optimizing Dual Antiplatelet Therapy Duration in Clinical Practice

To successfully implement these insights into routine healthcare workflows, multidisciplinary stroke teams must establish clear discharge and follow-up protocols. Clinical pharmacists and outpatient care coordinators play a vital role in ensuring patients transition smoothly from dual antiplatelet therapy to single antiplatelet monotherapy at day 21. Patient education is equally critical; individuals must understand the importance of strict compliance during the initial 21-day high-risk period, as well as the necessity of stepping down treatment to avoid long-term bleeding risks. Additionally, clinicians must routinely screen for individual bleeding risk factors, such as history of peptic ulcer disease, concurrent non-steroidal anti-inflammatory drug use, or advanced age, when selecting antiplatelet regimens. Future clinical trials will continue to refine antiplatelet selection based on genetic profiles, such as CYP2C19 metabolizer status, and novel antiplatelet combinations. Nevertheless, current evidence strongly supports a standardized 10 to 21-day dual antiplatelet strategy as the standard of care for patients with acute minor non-cardioembolic stroke presenting within 72 hours of symptom onset.

What is the recommended dual antiplatelet therapy duration for minor stroke presenting within 72 hours?

Research indicates that a short dual antiplatelet therapy duration of 10 to 21 days is optimal for minor ischemic stroke presenting within 72 hours. This timeframe significantly reduces 90-day recurrent vascular events compared to single antiplatelet monotherapy, without causing a significant increase in severe bleeding complications.

Why is extending dual antiplatelet therapy beyond 21 days discouraged in minor stroke patients?

Extending dual antiplatelet therapy beyond 21 days is discouraged because it offers no additional efficacy in preventing recurrent ischemic events. Furthermore, prolonged dual therapy cumulative exposure increases the risk of major gastrointestinal and intracranial bleeding, negating the early clinical benefits achieved during the initial high-risk post-stroke period.

Does initiating dual antiplatelet therapy within 72 hours increase severe bleeding risk?

No, initiating a short 10 to 21-day course of dual antiplatelet therapy within 72 hours of minor stroke onset does not significantly increase severe bleeding risk compared to single antiplatelet therapy. Propensity-weighted analyses demonstrate similar rates of major hemorrhagic events between the short-duration dual therapy and monotherapy groups.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu T et al. Optimal duration of dual antiplatelet therapy for minor stroke within 72 hours of symptom onset: a prospective cohort study. Stroke Vasc Neurol. 2025 Jun 30. doi: 10.1136/svn-2023-002933. PMID: 39277180.

2. Gao Y, Chen W, Pan Y, et al. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023;389(26):2413-2424.

3. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215-225.